MAIA Biotechnology (NASDAQ: MAIA) CEO insider buy totals 10,500 shares

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. reported an insider share purchase by its Chief Executive Officer, director and 10% owner Vlad Vitoc. On 11/25/2025, he bought 10,500 shares of common stock at a weighted average price of $0.9661 per share, with individual trades ranging from $0.9606 to $0.9745. After this transaction, he directly holds 831,421 common shares. An additional 210,000 shares are held by his spouse, which he reports as indirectly beneficially owned but disclaims ownership beyond his economic interest.

Insider Trade Summary

Net Buyer: 10,500 shares ($10,144)

Net Buy 2 txns

Insider Vitoc Vlad

Role Chief Executive Officer

Bought 10,500 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,500	$0.9661	$10K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 831,421 shares (Direct); Common Stock — 210,000 shares (Indirect, See Footnote)

Footnotes (1)

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9606 to $0.9745, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitoc Vlad

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		P		10,500	A	$0.9661(1)	831,421	D
Common Stock								210,000	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.9606 to $0.9745, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, to any security holder of the issuer, or to the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

2. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

	/s/ Vlad Vitoc	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MAIA (MAIA) disclose in this Form 4?

MAIA Biotechnology disclosed that its CEO, director and 10% owner Vlad Vitoc purchased 10,500 shares of MAIA common stock on 11/25/2025.

At what price did the MAIA CEO buy shares in this insider trade?

The reported purchase was at a weighted average price of $0.9661 per share, with individual trades between $0.9606 and $0.9745.

How many MAIA shares does Vlad Vitoc own after this transaction?

Following the reported transaction, Vlad Vitoc directly owns 831,421 shares of MAIA common stock.

What is the indirect MAIA share ownership reported for Vlad Vitoc?

An additional 210,000 MAIA shares are held by Mr. Vitoc’s spouse. He reports them as indirectly beneficially owned but disclaims beneficial ownership except for his pecuniary interest.

What does weighted average price mean in this MAIA insider purchase?

The weighted average price of $0.9661 means the 10,500 shares were bought in multiple trades between $0.9606 and $0.9745, and the average reflects all those trade prices.

Who is the reporting person in this MAIA Biotechnology Form 4 filing?

The reporting person is Vlad Vitoc, who serves as MAIA Biotechnology’s Chief Executive Officer, a director, and a 10% owner.